Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118613 | PMC |
| http://dx.doi.org/10.1016/S0140-6736(21)00893-X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Shared Class I HLA-bound Non-canonical Neoepitopes between Normal and Neoplastic Tissues of Pancreatic Adenocarcinoma.
Clin Cancer Res
December 2024
Johns Hopkins Medicine, Baltimore, Maryland, United States.
Purpose: Developing T cell or vaccine therapies for pancreatic ductal adenocarcinoma (PDAC) has been challenging due to a lack of knowledge regarding immunodominant, cancer-specific antigens, as a scarcity of genomic mutation-associated neoepitopes characterizes PDAC and there are limited availability of effective approaches to discover them.
Experimental Design: We utilized an advanced mass spectrometry approach to compare the immunopeptidome of PDAC tissues and matched normal tissues from the same patients.
Results: We identified HLA class I-binding variant peptides derived from canonical proteins, which had single amino-acid substitutions not attributed to genetic mutations or RNA editing.
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress.
J Hematol Oncol
December 2024
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, P. R. China.
Chimeric antigen receptor (CAR)-T cell therapy has emerged as one of the most rapidly evolving modalities of immunotherapy, with substantial success in the treatment of hematological malignancies and encouraging outcomes in solid tumors. Yet, the efficacy of CAR-T therapy is hindered by challenges such as suboptimal expansion and persistence, adverse events, a scarcity of ideal targets, high immunosuppression, and insufficient infiltration due to the intricate tumor microenvironment, all of which limit its application. The 2024 European Society for Medical Oncology (ESMO) Congress presented novel CAR-T cell therapies for hematologic and solid malignancies, focusing on strategies such as cytokine modulation, innovative targets, allogeneic development, mRNA vaccine synergy, in vivo delivery and conditional activation to surmount these challenges.
View Article and Find Full Text PDFBoosting the efficacy of fungal biocontrol: miRNA339-5p-mediated mosquito immunity regulation.
Pest Manag Sci
December 2024
State Key Laboratory of Green Pesticide, College of Plant Protection, South China Agricultural University, Guangzhou, China.
Article Synopsis
- Aedes mosquitoes spread serious diseases like dengue and zika, leading to a need for eco-friendly solutions due to insecticide resistance and few effective vaccines.
- This study explored the interaction between the fungus Metarhizium anisopliae and Aedes albopictus, finding that the fungal infection boosts the mosquitoes' immune response and activates specific immune genes that help fight off the fungus.
- Researchers discovered a microRNA called miR339-5p that regulates immune genes; using a synthetic version of this microRNA increased the fungus's effectiveness in killing mosquitoes, indicating a potential for genetic modifications to improve mosquito control methods.
The association between ozone exposure and blood pressure in a general Chinese middle-aged and older population: a large-scale repeated-measurement study.
BMC Med
November 2024
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, Fujian, China.
Background: The relationship between ozone (O) exposure and blood pressure (BP) remains inconclusive. Given the scarcity of Chinese epidemiological data, more research on this association is of paramount importance, particularly among middle-aged and older Chinese populations.
Methods: This study involved 10,875 participants (median age: 60.
Human CD34-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy.
Front Immunol
November 2024
Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
Article Synopsis
- Plasmacytoid dendritic cells (pDCs) are important for immune responses but are rare in blood and less effective in cancer, making their use in therapies difficult.
- Researchers developed a new method to differentiate pDCs from cord blood stem cells using specific growth factors like SR-1 and GM-CSF, leading to a significant yield of functional pDCs.
- The study found that these cord blood-derived pDCs closely resemble primary pDCs and can potentially enhance anti-tumor immune responses, making them promising candidates for cancer therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!